



## Supporting Figure S1



**Supporting Figure S1. NEDD4L is mainly expressed in monocyte-derived macrophages. (A)** Analysis of *Nedd4l* expression in Liver cells from healthy and patients with liver fibrosis by analyzing liver single-cell sequencing database (Liver Cell Atlas: <https://singlecell.broadinstitute.org>). **(B)** Representative immunofluorescence images of IBA1 (red), NEDD4L (green), and DAPI (white) (Scale bar: 20  $\mu$ m) in the livers of Oil or CCl<sub>4</sub>-treated *Nedd4l<sup>fl/fl</sup>* and *Nedd4l<sup>ΔMye</sup>* mice. The number of positive cells was quantified. Values represent mean  $\pm$  SEM. \*\*\* $p < 0.001$ .


## Supporting Figure S2



### Supporting Figure S2. *Nedd4l* deficiency in macrophages worsens BDL-induced liver fibrosis.


(A) Eight-week-old male *Nedd4<sup>ΔMyc</sup>* mice and their littermate *Nedd4<sup>fl/fl</sup>* mice were subjected to bile duct ligation model for 7 days to establish the experimental biliary stasis-related liver fibrosis model. (B) Representative immunofluorescence images of IBA1 (red), NEDD4L (green), and DAPI (white) (Scale bar: 20  $\mu$ m) in the livers of BDL-treated *Nedd4<sup>fl/fl</sup>* mice. (C) Representative images of Sirius red staining (Scale bar: 200  $\mu$ m) from *Nedd4<sup>fl/fl</sup>* and *Nedd4<sup>ΔMyc</sup>* mice are shown. The percentage of positive area was quantified. (D) The hepatic expression of *Acta2*, *Col3a1*, *Col1a1*, *Gpnmb*, *Cd9*, *Fabp5* and *Spp1* were analyzed by RT-qPCR in liver tissues from *Nedd4<sup>fl/fl</sup>* and *Nedd4<sup>ΔMyc</sup>* mice. Values represent mean  $\pm$  SEM. \* $p < 0.05$ .

## Supporting Figure S3




**Supporting Figure S3. Myeloid cell-specific knockout of *Nedd4l* does not affect immune cell infiltration and liver injury in  $\text{CCl}_4$ -induced liver fibrosis. (A)** Representative images of F4/80 staining (Scale bar: 200  $\mu\text{m}$ ), MPO staining (Scale bar: 200  $\mu\text{m}$ ) and CD3 staining (Scale bar: 200  $\mu\text{m}$ ) from oil and  $\text{CCl}_4$ -treated *Nedd4<sup>fl/fl</sup>* and *Nedd4<sup>ΔMye</sup>* mice are shown. The number of positive cells was quantified. **(B)** The hepatic expression of inflammatory genes was analyzed by RT-qPCR from *Nedd4<sup>fl/fl</sup>* and *Nedd4<sup>ΔMye</sup>* mice. **(C)** Serum ALT and AST levels were measured. Values represent mean  $\pm$  SEM.

## Supporting Figure S4




**Supporting Figure S4. Myeloid cell-specific knockout of *Nedd4l* does not affect immune cell infiltration in CDAHFD-induced liver fibrosis. (A)** Representative images of F4/80 staining (Scale bar: 200  $\mu$ m), MPO staining (Scale bar: 200  $\mu$ m) from CDAHFD-fed *Nedd4<sup>fl/fl</sup>* and *Nedd4<sup>ΔMye</sup>* mice are shown. The number of positive cells was quantified. **(B)** The hepatic expression of inflammatory genes was analyzed by RT-qPCR from *Nedd4<sup>fl/fl</sup>* and *Nedd4<sup>ΔMye</sup>* mice. Values represent mean  $\pm$  SEM.

## Supporting Figure S5




**Supporting Figure S5. *Nedd4l* deficiency in macrophage augments profibrotic signaling.** (A) Analysis of macrophage *CCL22*, *VEGFA*, *TLR1* expression in patients with liver fibrosis by analyzing single-cell sequencing database (Liver Cell Atlas: <https://singlecell.broadinstitute.org>). (B) Representative immunofluorescence images of IBA1 (red), CD206 (green), DAPI (white) (Scale bar: 10  $\mu$ m) from CCl<sub>4</sub>-treated *Nedd4l*<sup>fl/fl</sup> and *Nedd4l* <sup>$\Delta$ Mye</sup> mice are shown. The number of positive cells was quantified. Values represent mean  $\pm$  SEM. \*\*\**p*<0.001.

## Supporting Figure S6



**Supporting Figure S6. *Nedd4l* deficiency in macrophages does not affect inflammatory response and cell viability.** (A) Bone marrow-derived macrophages (BMDMs) were isolated from *Nedd4l*<sup>fl/fl</sup> and *Nedd4l* <sup>$\Delta$ Mye</sup> mice and stimulated with H<sub>2</sub>O (vehicle control) or LPS (100 ng/ml) for 3 hours. Cell viability was assessed using the CCK-8 assay. (B) RAW 264.7 cells were transfected with control siRNA (siCtrl) or *Nedd4l*-specific siRNA (si*Nedd4l*), and then stimulated with LPS (10 ng/ml) for 3 hours. The knockout efficiency and pro-inflammatory cytokines (*Tnfa*, *Il1b*, and *Il-6*) was analysis by qRT-PCR. Values represent mean  $\pm$  SEM. \**p*<0.05.

## Supporting Figure S7



**Supporting Figure S7. *Nedd4* deficiency in macrophages amplifies TGF- $\beta$ 1-driven pro-fibrotic polarization, enhancing the activation of co-cultured JS-1 cells.** (A) Schematic diagram of experimental design. BMDMs isolated from *Nedd4<sup>fl/fl</sup>* and *Nedd4<sup>ΔMye</sup>* mice were stimulated with M-CSF (20 ng/ml) for 7 days, and then stimulated with 10 ng/ml TGF- $\beta$ 1 for 24 hours, followed by removal of the supernatant and further culture in fresh medium for an additional 24 hours. Conditional BMDM medium were co-cultured with JS-1 cells. (B) The expression of fibrogenic genes was analyzed by RT-qPCR in JS-1 cells treated with conditional medium from *Nedd4<sup>fl/fl</sup>* and *Nedd4<sup>ΔMye</sup>* macrophages. Values represent mean  $\pm$  SEM. \* $p$ <0.05, \*\* $p$ <0.01.

**Supporting Table S1.** The list general characteristics of human samples.

Patient #	Gender	Age	Primary Diagnosis	ALT (IU/L)	AST (IU/L)
1	F	54	steatosis	38	25
2	M	52	steatosis	14	14
3	M	56	MASLD	26	18
4	M	30	MASLD	45	18
5	M	39	MASH, liver fibrosis	92	45
6	M	44	MASH, liver fibrosis	66	36

MASLD: Metabolic dysfunction-associated steatotic liver disease

MASH: Metabolic dysfunction-associated steatohepatitis

**Supporting Table S2:** The primer sequences for RT-qPCR.

Genes (mouse)	Forward primer (5'-3')	Reverse primer (5'-3')
<i>18s</i>	AAC TTT CGAT GGT AGT CGC CGT	TCCTTGGATGTGGTAGCCGTTT
<i>Acta2</i>	TCCTGACGCTGAAGTATCCGATA	GGTGCCAGATCTTTTCCATGTC
<i>Col1a1</i>	TAGGCCATTGTGTATGCAGC	ACATGTT CAGCTTTGTGGACC
<i>Col1a2</i>	GGTGAGCCTGGTCAAACGG	ACTGTGTCCTTTCACGCCTTT
<i>Col3a1</i>	TAGGACTGACCAAGGTGGCT	GGAACCTGGTTTCTTCTCACC
<i>Col4a1</i>	CACATTTTCCACAGCCAGAG	GTCTGGCTTCTGCTGCTCTT
<i>Fn1</i>	TTCAAGTGTGATCCCCATGAAG	CAGGTCTACGGCAGTTGTCA
<i>Vimentin</i>	TCCACACGCACCTACAGTCT	CCGAGGACCGGGTACATA
<i>Tgfb1</i>	CAACCAGGTCCTTCTAAA	GGAGAGCCCTGGATACCAAC
<i>Trem2</i>	CTGGAACCGTCACCATCACTC	CGAAACTCGATGACTCCTCGG
<i>Cd9</i>	TGGGATTGTTCTTCGGGTTCC	TCCTTGTGGGTATAGCCCCAG
<i>Spp1</i>	AGCAAGAAACTCTTCCAAGCAA	GTGAGATTCGTCAGATTCATCCG
<i>Gpmb</i>	AGAAATGGAGCTTTGTCTACGTC	CTTCGAGATGGGAATGTATGCC
<i>Fabp5</i>	AAAGAGCTAGGAGTAGGACTGG	TGTTGCCATCACACGTAATGA
<i>Cd63</i>	GAAGCAGGCCATTACCCATGA	TGACTTCACCTGGTCTCTAAACA
<i>Chil3(Ym1/2)</i>	CAGGTCTGGCAATTCTTCTGAA	GTCTTGCTCATGTGTGTAAGTGA
<i>Ccl22</i>	CTCTGCCATCACGTTTAGTGAA	GTCTTGCTCATGTGTGTAAGTGA
<i>Tlr8</i>	GCCAAACAACAGCACCCAAAT	AGGCAACCCAGCAGGTATAGT
<i>Vegfa</i>	GCACATAGAGAGAATGAGCTTCC	CTCCGCTCTGAACAAGGCT
<i>Arg1</i>	CTCCAAGCCAAAGTCCTTAGAG	AGGAGCTGTCATTAGGGACATC
<i>Nedd4l</i>	GTCCGGCTGTTCCGTACTC	AGGCCATAGTAGGGGTAAACAT
<i>Timp1</i>	GCAACTCGGACCTGGTCATAA	CGGCCCGTGATGAGAAACT
<i>F480</i>	GGAAAGCACCATGTTAGCTGC	CCTCTGGCTGCCAAGTTAATG
<i>Ly6g</i>	TGCGTTGCTCTGGAGATAGA	CAGAGTAGTGGGGCAGATGG
<i>Il1b</i>	GCAACTCGGACCTGGTCATAA	CGGCCCGTGATGAGAAACT
<i>Il6</i>	TAGTCCTTCTACCCCAATTTCC	TTGGTCCTTAGCCACTCCTTC
<i>Tnfa</i>	AGGCTGCCCGACTACGT	GACTTTCTCTGGTATGAGATAGCAAA
<i>Ccl2</i>	CCAGCCTACTCATTGGGAT	GGGCCTGCTGTTACAGTT
<i>Cxcl1</i>	ACTGCACCCAAACCGAAGTC	TGGGGACACCTTTTAGCATCTT
<i>Mmp1</i>	CTTCTTCTTGTTGAGCTGGACTC	CTGTGGAGGTCAGTGTAGACT

Genes (human)	Forward primer (5'-3')	Reverse primer (5'-3')
<i>18S</i>	GGCCCTGTAATTGGAATGAGTC	CCAAGATCCAACACTACGAGCTT
<i>ACTA2</i>	GTGACGAAGCACAGAGCAAA	CTTTTCCATGTCGTCCCAGT
<i>COL1A1</i>	CAGATCACGTCATCGCACAA	TGTGAGGCCACGCATGAG
<i>COL3A1</i>	AGGACTGACCAAGATGGGAA	AGGGGAGCTGGCTACTTCTC
<i>COL4A1</i>	CCTTTTGTCCCTTCACTCCA	CTCCACGAGGAGCACAGC
<i>FN1</i>	CGGTGGCTGTCAGTCAAAG	AAACCTCGGCTTCCTCCATAA
<i>TGFB1</i>	CAATTCCTGGCGATACCTCAG	GCACAACTCCGGTGACATCAA